NYSE:AZN - AstraZeneca Stock Price, Forecast & News

AstraZeneca trades on the New York Stock Exchange (NYSE) under the ticker symbol "AZN."

AstraZeneca announced a semiannual dividend on Friday, February 15th. Shareholders of record on Friday, March 1st will be given a dividend of $0.95 per share on Wednesday, March 27th. This represents a yield of 4.64%. The ex-dividend date is Thursday, February 28th. This is an increase from AstraZeneca's previous semiannual dividend of $0.45. View AstraZeneca's Dividend History.

AstraZeneca's stock split on Monday, July 27th 2015. The 2-1 split was announced on Friday, June 26th 2015. The newly issued shares were payable to shareholders after the market closes on Friday, July 24th 2015. An investor that had 100 shares of AstraZeneca stock prior to the split would have 200 shares after the split.

AstraZeneca plc (NYSE:AZN) posted its quarterly earnings results on Thursday, October, 24th. The company reported $0.50 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.45 by $0.05. The company had revenue of $6.13 billion for the quarter, compared to analyst estimates of $6.07 billion. AstraZeneca had a net margin of 8.42% and a return on equity of 38.63%. The business's quarterly revenue was up 14.8% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.71 earnings per share. View AstraZeneca's Earnings History.

AstraZeneca is scheduled to release their next quarterly earnings announcement on Friday, February 14th 2020. View Earnings Estimates for AstraZeneca.

AstraZeneca will be holding an earnings conference call on Friday, February 14th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

14 brokers have issued twelve-month price objectives for AstraZeneca's stock. Their forecasts range from $40.73 to $57.00. On average, they anticipate AstraZeneca's stock price to reach $50.68 in the next twelve months. This suggests a possible upside of 3.6% from the stock's current price. View Analyst Price Targets for AstraZeneca.

14 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AstraZeneca in the last year. There are currently 4 sell ratings, 2 hold ratings and 8 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for AstraZeneca.

Headlines about AZN stock have trended somewhat negative this week, InfoTrie Sentiment reports. The research firm identifies negative and positive news coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. AstraZeneca earned a media sentiment score of -1.4 on InfoTrie's scale. They also assigned media coverage about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the company's share price in the next few days. View News Stories for AstraZeneca.

Some companies that are related to AstraZeneca include Johnson & Johnson (JNJ), Roche Holdings AG Basel (RHHBY), Pfizer (PFE), Merck & Co., Inc. (MRK), Novartis (NVS), Abbott Laboratories (ABT), Novo Nordisk A/S (NVO), Eli Lilly And Co (LLY), AbbVie (ABBV), Sanofi (SNY), GlaxoSmithKline (GSK), Bristol-Myers Squibb (BMY), Commonwealth Bank of Australia (CSLLY), Bayer (BAYRY) and Celgene (CELG).

Based on aggregate information from My MarketBeat watchlists, some companies that other AstraZeneca investors own include Pfizer (PFE), AT&T (T), AbbVie (ABBV), Bank of America (BAC), Merck & Co., Inc. (MRK), Cisco Systems (CSCO), Gilead Sciences (GILD), Micron Technology (MU), Netflix (NFLX) and Exxon Mobil (XOM).

AstraZeneca's stock is owned by a number of of institutional and retail investors. Top institutional investors include Janney Capital Management LLC (0.02%), Galibier Capital Management Ltd. (0.01%), Cookson Peirce & Co. Inc. (0.01%), Vigilant Capital Management LLC (0.01%), Park National Corp OH (0.01%) and CWM LLC (0.01%). View Institutional Ownership Trends for AstraZeneca.

AZN stock was sold by a variety of institutional investors in the last quarter, including Janney Capital Management LLC, CWM LLC, Cookson Peirce & Co. Inc., United Services Automobile Association, Clean Yield Group, TIAA FSB, Archford Capital Strategies LLC and Sound View Wealth Advisors Group LLC. View Insider Buying and Selling for AstraZeneca.

AZN stock was acquired by a variety of institutional investors in the last quarter, including Galibier Capital Management Ltd., FNY Investment Advisers LLC, Mckinley Capital Management LLC Delaware, AE Wealth Management LLC, Park National Corp OH, First Citizens Financial Corp, J.W. Cole Advisors Inc. and We Are One Seven LLC. View Insider Buying and Selling for AstraZeneca.

Shares of AZN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of AZN stock can currently be purchased for approximately $48.90.

AstraZeneca has a market capitalization of $128.30 billion and generates $22.09 billion in revenue each year. The company earns $2.16 billion in net income (profit) each year or $1.73 on an earnings per share basis. AstraZeneca employs 64,400 workers across the globe.View Additional Information About AstraZeneca.

The official website for AstraZeneca is http://www.astrazeneca.com/.

AstraZeneca's mailing address is 1 FRANCIS CRICK AVENUE CAMBRIDGE BIOMEDICAL CAMPUS, CAMBRIDGE X0, CB2 0AA. The company can be reached via phone at 44-20-3749-5000 or via email at [email protected]